Growth Hormone
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Short Bowel Syndrome
Conditions
Short Bowel Syndrome
Trial Timeline
Sep 1, 2003 → Oct 20, 2008
NCT ID
NCT00742157About Growth Hormone
Growth Hormone is a approved stage product being developed by Eli Lilly for Short Bowel Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00742157. Target conditions include Short Bowel Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00742157 | Approved | Terminated |
Competing Products
20 competing products in Short Bowel Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| somatropin + leuprorelin | Eli Lilly | Phase 3 | 77 |
| Pancreatic Enzyme | AbbVie | Phase 2 | 52 |
| Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth Hormone | AstraZeneca | Phase 3 | 77 |
| Oral, live, pentavalent rotavirus vaccine; RotaTeq(R) | Merck | Phase 1 | 33 |
| Saizen® + Saizen® | Merck | Phase 3 | 77 |
| r-metHuLeptin | Amgen | Phase 1 | 32 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 2 | 51 |
| Somatotropin growth hormone recombinant human | Pfizer | Approved | 84 |
| Genotropin (somatropin) | Pfizer | Approved | 84 |
| Genotropin + Genotropin | Pfizer | Phase 3 | 76 |
| GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatment | Pfizer | Approved | 84 |
| Genotropin | Pfizer | Phase 2/3 | 64 |
| glepaglutide | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide | Zealand Pharma | Phase 3 | 74 |
| ZP1848 | Zealand Pharma | Phase 2 | 49 |
| glepaglutide + Placebo | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide 10 mg | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide | Zealand Pharma | Phase 3 | 74 |
| Nutropin [Somatropin (rDNA origin) for injection] | Ipsen | Approved | 82 |